Compare Prologis Inc (PLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Recursion Pharmaceuticals Inc — how do they compare? Prologis Inc trades at $136.97 (market cap $131.60B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Prologis Inc is far larger — about 70.8× Recursion Pharmaceuticals Inc's market cap, and Prologis Inc pays a 3.09% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PLD | RXRX | |
|---|---|---|
Market Cap | $131.60B | $1.86B |
Sector | Real Estate | Health |
52-Week High | $149.96 | $6.79 |
52-Week Low | $110.98 | $2.84 |
Enterprise Value | $166.34B | $1.38B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.13 exceeding the $0.747 estimate. Revenue grew to $8.79 billion in 2025, though net income margin dipped to 37.86%. The stock faces headwinds from a high P/E of 30.84 and rising debt-to-asset ratio, now at 37.2% for 2025. Recent news highlights institutional buying interest amid market volatility.
The outlook for PLD is mixed, with analyst consensus bullish (59.52% buy ratings) and a $160.13 price target suggesting 15.6% upside. Key opportunities include sustained revenue growth and dividend stability, but risks involve elevated valuation, debt levels, and macroeconomic sensitivity. The stock's performance hinges on Q3 2026 earnings and the integration of the SEGRO acquisition.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
